Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and
toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy
versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally
recurrent nasopharyngeal carcinoma.